CellCentric raises $220m to advance trials of oral myeloma drug
CellCentric has completed an oversubscribed $220 million Series D financing led by Venrock Healthcare Capital Partners, with participation from new and existing investors. The proceeds will support clinical trials for multiple myeloma therapy inobrodib. These will include continued enrolment of the company’s Phase II DOMMINO-1 study and… Read More
